Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IMNM 
Immunome Inc (IMNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IMNM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.94% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 544.31M USD | Price to earnings Ratio - | 1Y Target Price 27.14 |
Price to earnings Ratio - | 1Y Target Price 27.14 | ||
Volume (30-day avg) 1115051 | Beta 1.94 | 52 Weeks Range 6.19 - 22.02 | Updated Date 04/1/2025 |
52 Weeks Range 6.19 - 22.02 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.6075 | Actual -1.11 |
Profitability
Profit Margin - | Operating Margin (TTM) -2030.61% |
Management Effectiveness
Return on Assets (TTM) -49.34% | Return on Equity (TTM) -194.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 371402648 | Price to Sales(TTM) 60.2 |
Enterprise Value 371402648 | Price to Sales(TTM) 60.2 | ||
Enterprise Value to Revenue 41.08 | Enterprise Value to EBITDA -0.72 | Shares Outstanding 86950704 | Shares Floating 69554437 |
Shares Outstanding 86950704 | Shares Floating 69554437 | ||
Percent Insiders 16.23 | Percent Institutions 57.67 |
Analyst Ratings
Rating 4.71 | Target Price 30 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Immunome Inc
Company Overview
History and Background
Immunome, Inc. (IMNM) was founded in 2012. It is a biotechnology company focused on discovering and developing first-in-class antibody therapeutics to treat and potentially cure cancer.
Core Business Areas
- Drug Discovery & Development: Immunome's core business involves discovering, developing, and commercializing antibody-based therapies for cancer. They use proprietary human memory B cell hybridoma technology.
Leadership and Structure
Purnanand Sarma is the President and CEO. The company has a typical organizational structure for a biotechnology firm, including research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- IMM-ONC-001: IMM-ONC-001 is a preclinical stage antibody targeting solid tumors. Details on market share and revenue are not yet available, as the product is still in development. Competitors include companies developing similar antibody therapeutics, such as Regeneron, Genmab, and Xencor. Focus on Epithelial-Mesenchymal Transition (EMT) targets.
- COVID-19 Antibody Program: In early stages, Immunome had an antibody program targeting COVID-19 but has since divested. Competitors in this space included Regeneron, Eli Lilly, and Vir Biotechnology. No revenue or market share data available.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The market for antibody therapeutics is substantial and growing, driven by advancements in immuno-oncology.
Positioning
Immunome is positioned as an innovative antibody discovery company using a unique approach to identify novel targets and develop first-in-class therapeutics. Its competitive advantage lies in its proprietary technology platform.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars, with the antibody therapeutics portion representing a significant fraction. Immunome aims to capture a portion of this market with its innovative therapies. The TAM for antibody therapeutics could exceed $100 Billion by 2030.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Focus on novel targets and first-in-class therapeutics
- Experienced management team
- Strong scientific rationale for its approach
Weaknesses
- Early-stage development pipeline
- Limited financial resources compared to larger competitors
- High risk associated with drug development
- Dependence on partnerships for later-stage development
Opportunities
- Potential for breakthrough therapies in cancer
- Strategic partnerships with larger pharmaceutical companies
- Expansion of its technology platform to other disease areas
- Favorable regulatory environment for innovative therapies
Threats
- Clinical trial failures
- Competition from established players
- Regulatory delays
- Economic downturn impacting R&D funding
Competitors and Market Share
Key Competitors
- REGN
- GMAB
- XNCR
Competitive Landscape
Immunome faces strong competition from established biotechnology and pharmaceutical companies with greater resources and more advanced pipelines. Its advantage lies in its unique discovery platform, which could lead to novel and differentiated therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of its technology platform and preclinical pipeline.
Future Projections: Future growth depends on clinical trial success, partnerships, and regulatory approvals. Analyst estimates will be highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing IMM-ONC-001 and exploring other targets using its discovery platform.
Summary
Immunome is an early-stage biotechnology company with a promising antibody discovery platform. It has no revenue currently, thus it has high-risk as it is pre-revenue. Successful clinical trials and strategic partnerships are crucial for its future success. Immunome needs to carefully manage its cash burn and navigate the competitive landscape effectively.
Similar Companies
GMAB
Genmab AS
GMAB
Genmab AS
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
XNCR
Xencor Inc
XNCR
Xencor Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunome Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-10-02 | Chairman, President & CEO Dr. Clay B. Siegall Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 118 | Website https://immunome.com |
Full time employees 118 | Website https://immunome.com | ||
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.